Summa Equity Acquires Majority Stake in Sengenics

Standard BioTools Acquires Sengenics from Summa Equity

November 21, 2024

Biotechnology

Standard BioTools Inc. has acquired Sengenics Corporation Pte Ltd, a Summa Equity portfolio company, to broaden its proteomics and antibody‑profiling capabilities. The deal will integrate Sengenics' KREX™ immunoproteomics and i-OME™ Discovery platform with Standard BioTools' SomaScan/proteomics offerings to enhance biomarker discovery and accelerate drug development.

Summa Equity Acquires Majority Stake in Axion BioSystems

July 15, 2021

Medical Devices

Summa Equity Fund II has acquired a majority stake in Axion BioSystems, a US life science tools company that develops MEA (microelectrode array) and impedance-based bioelectronic assay technologies. Summa plans to support Axion's commercial scale-up and global growth to accelerate adoption of its platforms across academia and biopharma, particularly in cell and gene therapy and drug discovery applications.

Summa Equity Acquires Olink Proteomics

March 13, 2019

Biotechnology

Summa Equity has acquired a majority stake in Olink Proteomics (Olink AB), a Uppsala-based life science company specializing in proteomics and protein biomarker discovery. The transaction is financed with senior secured/unitranche financing provided by EQT Credit and will support Olink's global scaling and continued product and service development.

Summa Equity Acquires Majority Stake in Nutris

September 3, 2024

Food & Beverage

Impact investor Summa Equity has acquired a majority stake in Nutris, a Croatian plant-based protein ingredients manufacturer founded in 2019. The investment will support scaling Nutris’s manufacturing capacity and R&D to expand production of fava-bean protein isolates and other plant-based ingredients for food, sports nutrition and dairy/meat alternative markets.

Summa Equity Acquires Majority Stake in myneva

June 30, 2021

Software

Summa Equity Fund II has acquired a majority stake in myneva, a Hamburg‑based European software provider offering SaaS solutions for the social care sector. myneva serves around 2,000 customers across six European countries, has approximately 220 employees and €30m in revenue; Summa intends to support further digitization, international expansion and continued growth.

SK Capital Partners Acquires Majority Stake in SEQENS

December 16, 2021

Pharmaceuticals

Funds advised by SK Capital Partners acquired a majority shareholding in SEQENS, investing alongside Bpifrance, Nov Santé, Mérieux Equity Partners, Ardian, Eximium and SEQENS' management. The deal includes the integration of Wavelength Pharmaceuticals into SEQENS and the prior divestiture of certain non-core mineral specialties assets; SEQENS emerges as a strengthened pharmaceutical CDMO with ~€1.1bn revenue and ~3,200 employees.